

Beatrice Labrosse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2710044/publications.pdf>

Version: 2024-02-01

14
papers

637
citations

840776

11
h-index

1058476

14
g-index

14
all docs

14
docs citations

14
times ranked

1031
citing authors

#	ARTICLE	IF	CITATIONS
1	Natural History of Sudan ebolavirus to Support Medical Countermeasure Development. <i>Vaccines</i> , 2022, 10, 963.	4.4	4
2	Stability and antiviral activity against human cytomegalovirus of artemisinin derivatives. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 34-40.	3.0	47
3	High level of susceptibility to human TRIM5 α conferred by HIV-2 capsid sequences. <i>Retrovirology</i> , 2013, 10, 50.	2.0	18
4	A Genetically Engineered Waterfowl Influenza Virus with a Deletion in the Stalk of the Neuraminidase Has Increased Virulence for Chickens. <i>Journal of Virology</i> , 2010, 84, 940-952.	3.4	124
5	Detection of Extensive Cross-Neutralization between Pandemic and Seasonal A/H1N1 Influenza Viruses Using a Pseudotype Neutralization Assay. <i>PLoS ONE</i> , 2010, 5, e11036.	2.5	28
6	Enhancement of the Influenza A Hemagglutinin (HA)-Mediated Cell-Cell Fusion and Virus Entry by the Viral Neuraminidase (NA). <i>PLoS ONE</i> , 2009, 4, e8495.	2.5	101
7	<i>In vivo</i> selection by enfuvirtide of HIV type-1 <i>env</i> quasispecies with optimal potential for phenotypic expression of HR1 mutations. <i>Antiviral Therapy</i> , 2009, 14, 597-602.	1.0	4
8	Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses. <i>Retrovirology</i> , 2008, 5, 23.	2.0	9
9	Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection. <i>Retrovirology</i> , 2008, 5, 93.	2.0	16
10	Impact of Natural Polymorphism within the gp41 Cytoplasmic Tail of Human Immunodeficiency Virus Type 1 on the Intracellular Distribution of Envelope Glycoproteins and Viral Assembly. <i>Journal of Virology</i> , 2007, 81, 125-140.	3.4	30
11	Role of the Envelope Genetic Context in the Development of Enfuvirtide Resistance in Human Immunodeficiency Virus Type 1-Infected Patients. <i>Journal of Virology</i> , 2006, 80, 8807-8819.	3.4	59
12	Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors. <i>Journal of Virology</i> , 2003, 77, 1610-1613.	3.4	92
13	Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. <i>Aids</i> , 2003, 17, 809-814.	2.2	41
14	Cooperation of the V1/V2 and V3 Domains of Human Immunodeficiency Virus Type 1 gp120 for Interaction with the CXCR4 Receptor. <i>Journal of Virology</i> , 2001, 75, 5457-5464.	3.4	64